0000914190-21-000213.txt : 20210810 0000914190-21-000213.hdr.sgml : 20210810 20210810181954 ACCESSION NUMBER: 0000914190-21-000213 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210806 FILED AS OF DATE: 20210810 DATE AS OF CHANGE: 20210810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Eansor Norman David CENTRAL INDEX KEY: 0001270905 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17272 FILM NUMBER: 211161379 MAIL ADDRESS: STREET 1: 8100 SOUTHPARK WAY, A-8 CITY: LITTLETON STATE: CO ZIP: 80120 FORMER NAME: FORMER CONFORMED NAME: EANSOR N DAVID DATE OF NAME CHANGE: 20031120 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIO-TECHNE Corp CENTRAL INDEX KEY: 0000842023 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 411427402 STATE OF INCORPORATION: MN FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 614 MCKINLEY PL N E CITY: MINNEAPOLIS STATE: MN ZIP: 55413 BUSINESS PHONE: 6123798854 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 FORMER COMPANY: FORMER CONFORMED NAME: TECHNE CORP /MN/ DATE OF NAME CHANGE: 19920703 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-08-06 0000842023 BIO-TECHNE Corp TECH 0001270905 Eansor Norman David 8100 SOUTHPARK WAY, A-8 LITTLETON CO 80120 0 1 0 0 President-Protein Sciences Common Stock 2021-08-08 4 M 0 2537 0 A 3855 D Common Stock 2021-08-08 4 F 0 999 481.82 D 2856 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 11982 11982 D Stock Options (Right to Buy) 125.05 2024-08-09 Common Stock 15976 15976 D Restricted Stock Units 2021-08-08 4 M 0 2537 0 D Common Stock 2537 0 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 13550 13550 D Stock Options (Right to Buy) 177.32 2025-08-08 Common Stock 18066 18066 D Restricted Stock Units Common Stock 3151 3151 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 15948 15948 D Stock Options (Right to Buy) 190.41 2026-08-07 Common Stock 21265 21265 D Restricted Stock Units Common Stock 2575 2575 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 11488 11488 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 15318 15318 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 24975 24975 D Stock Options (Right to Buy) 267.87 2027-08-05 Common Stock 24975.0 24975.0 D Restricted Stock Units 2021-08-06 4 A 0 1556 0 A Common Stock 1556 1556 D Stock Options (Right to Buy) 481.82 2021-08-06 4 A 0 6080 0 A 2028-08-06 Common Stock 6080 6080 D Stock Options (Right to Buy) 481.82 2021-08-06 4 A 0 8107 0 A 2028-08-06 Common Stock 8107 8107 D Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Fully exercisable. Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 3,830 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 3,829 shares vest on each of 8/5/2023 and 8/5/2024. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021. Options to purchase 8,325 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025. /s/ Brenda S. Furlow as Attorney-in-Fact for N. David Eansor pursuant to Power of Attorney previously filed. 2021-08-10